report_lead_image_with_gradient.png
Q3 2026

Biopharma Report: A Disciplined Recovery, Led by Exits

Download this Report
To download this report, please complete the form below

PitchBook clients can access the full report and Excel data pack via the Research Center on the PitchBook Platform.

The biopharma VC recovery continues in 2026 despite the Q3 contraction

Biopharma VC deal value fell 25% QoQ to $8.4 billion in Q3. Without Isomorphic Labs’ $2.1 billion Series B in Q2, Q3 deal value slipped by about 7%, roughly in line with the dip in deal count. 2026 funding is still pacing 8% ahead of 2025, and the trailing four-quarter average of $9.4 billion sits well above the $7 billion quarterly average of 2023-2024.

Investors remain selective. Seed and early-stage rounds have taken their smallest share of deal value this year as capital has followed de-risked clinical assets, while small molecules have regained the top segment on the back of AI-enabled discovery platforms.

Exits cooled from Q2’s record but held up well. Q3 produced $15.3 billion in exit value, the second-strongest quarter since 2022, split almost evenly between acquisitions and IPOs. At 16, it had the most public listings of the past five quarters, although they tended to be smaller than the record-setting raises in Q2. 2026 exit value has already topped 180% of 2025’s full-year total.


Q3 VC deal value fell 25% to $8.4 billion, but 2026 YTD funding is still pacing 8% ahead of the same period in 2025.




Table of contents
Quarterly analysis 2
Biopharma landscape 5
VC activity 6
References 35